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4E‐BP1 as an oncotarget
Qing‐Bai She

maximally inhibit 4E-BP1 phosphorylation and
subsequent induction of 4E-BP1 binding to eIF4E to
prevent cap-dependent translation of oncogenic mRNAs
(e.g. survivin) and ultimately achieve antitumor activity.
Furthermore, we showed that a genetically-modified
non-phosphorylated 4E-BP1 mutant that binds
constitutively to eIF4E and represses eIF4E-dependent
oncogene expression exerts similar inhibitory effects on
tumor growth and metastasis as the combined
pharmacological inhibition of AKT and ERK pathways,
whereas loss of 4E-BP1 expression induces epithelialmesenchymal transition through translational control of
snail expression and its activity to promote metastatic
progression of CRC and reduce CRC dependence on
AKT/ERK signaling for translation, survival and
motility. Collectively, these findings support the
conclusion
that
deregulation
of
4E-BP1
phosphorylation-mediated
assembly
of
eIF4F
translation initiation complex causes CRC resistance to
its upstream kinase targeted therapies and thus maintain
the transformed phenotype for CRC progression and
metastasis. Of notice, several lines of evidence have
also established incomplete inhibition of 4E-BP1
phosphorylation, amplification of eIF4E or increased
eIF4E/4E-BP ratio as a mechanism of primary
resistance to anti-PI3K/AKT/mTOR and antiBRAF/MEK/ERK pathway inhibitors in a variety of
cancers [4-6].
Our data and others strongly suggest that 4E-BP1
phosphorylation is an important biomarker and
therapeutic target in cancer. It is well know that mTOR
kinase complex 1 (mTORC1) phosphorylates 4E-BP1,
which in turn, activates cap-dependent translation and
promotes protein synthesis. Our recent studies
demonstrated that the effects of AKT and ERK
activation on translational regulation of CRC
progression are largely mediated by mTORC1 [2],
suggesting that targeting mTOR is an attractive strategy
for cancer therapy. Nevertheless, incomplete inhibition
of 4E-BP1 phosphorylation and a concomitant
activation of AKT via loss of a negative feedback
mechanism by mTOR inhibitors, including rapalogs and
mTOR kinase inhibitors, have been implicated in
reduction of their therapeutic efficacy. Our most recent
findings revealed a critical role of PRAS40, a mTORC1
inhibitor, as a key integrator of mTORC1 and AKT

The cap-dependent mRNA translation process that
enables post-transcriptional control of gene expression
and protein synthesis is tightly regulated in eukaryotes.
Deregulation of this process, particularly in the
formation of the eIF4F translation initiation complex—
comprising the eIF4E mRNA cap-binding protein, the
eIF4G scaffolding protein and the eIF4A RNA
helicase—is associated with cancer development and
progression. It is widely believed that translation of
certain key oncogenic mRNAs is strongly dependent on
the level of eIF4E. Consequently, expression of these
oncogenic mRNAs is preferentially and disproportionately affected by eIF4E availability and is
sensitive to alteration of its level. Free eIF4E level can
be increased substantially in cancer cells by a number of
mechanisms, including elevated eIF4E expression,
decreased expression of eIF4E inhibitory binding
proteins, 4E-BPs, and release of eIF4E from 4E-BPs by
inactivating phosphorylation of 4E-BPs results from the
oncogenic
activation
of
PI3K/AKT
and
RAS/RAF/MEK/ERK signaling pathways.
Our recent studies have revealed that 4E-BP1 is a
critical regulatory node that integrates oncogenic signals
of the P3K/AKT and RAS/RAF/MEK/ERK pathways
for cancer progression and metastasis [1-3]. Mutations
in genes that encode components of these two pathways
occur at high frequency in cancer. Moreover, the AKT
and ERK pathways are often concurrently activated by
separate mutations in many human tumors. For
instance, KRAS and PIK3CA mutation occur
simultaneously in colorectal carcinoma; BRAF and
PIK3CA mutation in thyroid carcinoma; and BRAF and
PTEN mutation occur simultaneously in melanoma. A
number of small molecule inhibitors targeting
components of these two pathways have been tested for
the treatment of cancer in preclinical and clinical
studies, but have shown only limited activity as a single
agent. Our work demonstrated that in tumors such as
colorectal cancer (CRC) with coexistent activation of
both PI3K/AKT and RAS/ERK pathways, drug
resistance, following inhibition of either pathway, is
associated with redundant activation of eIF4E-initiated
cap-dependent
translation
through
convergent
phosphorylation of the translational repressor 4E-BP1
mediated by the AKT and ERK pathways. We found
that combined inhibition of both pathways is required to
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signaling for 4E-BP1-mediated translational regulation
of tumor progression, and indicated that the redundant
phosphorylation of PRAS40 on Ser183 and Thr246 sites
by both mTORC1 and AKT signaling is a novel
mechanistic basis for the acquired resistance to mTOR
inhibitors in cancer cells [7].
Our findings further suggest that directly targeting the
convergence of multiple oncogenic signals on eIF4F
translation initiation complex may provide a promising
strategy for improving cancer therapy. Several
translation initiation inhibitors, including eIF4E
antisense-oligonucleotides and the eIF4A inhibitor
silvestrol, have recently produced encouraging antitumor effects with limited toxicity. Future works require
additional clinical correlative studies and await the
development of clinically effective translation initiation
inhibitors for cancer treatment, either as single agents or
as part of combination therapy.
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